ERBB2 and triple-negative breast carcinoma: BRCA1 pathogenic variant carriers are more likely to be diagnosed with a triple negative breast cancer (i.e., estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor receptor 2 (HER2) negative), which is associated with poor prognosis due to limited therapeutic options [9].